GPR101

Summary

GPR101 (G protein-coupled receptor 101, HGNC:14963) is a protein-coding gene on chromosome Xq26.3, encoding Probable G-protein coupled receptor 101 (Q96P66). Orphan receptor.

The protein encoded by this gene is an orphan G protein-coupled receptor of unknown function. The encoded protein is a member of a family of proteins that contain seven transmembrane domains and transduce extracellular signals through heterotrimeric G proteins.

Source: NCBI Gene 83550 — RefSeq curated summary.

At a glance

• Gene–disease (curated): pituitary adenoma, growth hormone-secreting, 2 (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 1
• Clinical variants (ClinVar): 90 total — 1 pathogenic
• Phenotypes (HPO): 107
• Druggable target: yes
• MANE Select transcript: NM_054021

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14963
Approved symbol	GPR101
Name	G protein-coupled receptor 101
Location	Xq26.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000165370
Ensembl biotype	protein_coding
OMIM	300393
Entrez	83550

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000651716

RefSeq mRNA: 1 — MANE Select: NM_054021 NM_054021

CCDS: CCDS14662

Canonical transcript exons

ENST00000651716 — 2 exons

Exon	Start	End
ENSE00003841647	137023929	137031766
ENSE00003849256	137033802	137033995

Expression profiles

Bgee: expression breadth broad, 23 present calls, max score 76.08.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2248 / max 88.2878, expressed in 48 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200685	0.2248	48

Top tissues by expression

238 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nucleus accumbens	UBERON:0001882	76.08	gold quality
caudate nucleus	UBERON:0001873	64.50	gold quality
hypothalamus	UBERON:0001898	62.14	gold quality
putamen	UBERON:0001874	61.95	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	53.04	gold quality
cardia of stomach	UBERON:0001162	52.54	gold quality
biceps brachii	UBERON:0001507	52.08	gold quality
parotid gland	UBERON:0001831	52.00	gold quality
trabecular bone tissue	UBERON:0002483	50.15	gold quality
quadriceps femoris	UBERON:0001377	50.11	gold quality
vastus lateralis	UBERON:0001379	49.97	gold quality
pigmented layer of retina	UBERON:0001782	48.96	gold quality
bone marrow cell	CL:0002092	47.95	gold quality
deltoid	UBERON:0001476	44.43	gold quality
tongue	UBERON:0001723	44.17	gold quality
forebrain	UBERON:0001890	43.68	gold quality
body of tongue	UBERON:0011876	43.41	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
brain	UBERON:0000955	42.87	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
skeletal muscle tissue	UBERON:0001134	41.63	gold quality
bone marrow	UBERON:0002371	41.52	gold quality
colonic mucosa	UBERON:0000317	41.36	gold quality
superficial temporal artery	UBERON:0001614	41.33	gold quality
middle temporal gyrus	UBERON:0002771	41.13	gold quality
palpebral conjunctiva	UBERON:0001812	41.10	gold quality
mucosa of paranasal sinus	UBERON:0005030	40.98	gold quality
dorsal plus ventral thalamus	UBERON:0001897	40.83	gold quality
subthalamic nucleus	UBERON:0001906	40.78	gold quality
amniotic fluid	UBERON:0000173	40.69	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.12

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 12)

• GPR101 is a critical requirement for GnRH-(1-5) transactivation of EGFR in Ishikawa cells. (PMID:24264576)
• X-linked acrogigantism is caused by an Xq26.3 genomic duplication and is characterized by early-onset gigantism. Also found recurrent mutation in GPR101 in some adults with acromegaly. (PMID:25470569)
• Germline GPR101 mutations are very rare in patients with sporadic pituitary adenomas of various histotypes. (PMID:26792934)
• This study did not identify GPR101 abnormalities as a frequent cause of growth hormone deficiency. (PMID:26797872)
• p.E308D variant not found in acromegaly cases (PMID:26815903)
• Study showed that X-linked acrogigantism (XLAG) can result from germline or somatic duplication of GPR101. Duplication of GPR101 alone is sufficient for the development of XLAG, implicating it as the causative gene within the Xq26.3 region. The pathological features of XLAG-associated pituitary adenomas are typical and, together with the clinical phenotype, should prompt genetic testing. (PMID:27245663)
• This study shows that different GPR101 transcripts exist and that the brain is the major site of GPR101 expression across different species, although divergent species- and temporal-specific expression patterns are evident. These findings suggest an important role for GPR101 in brain and pituitary development and likely reflect the very different growth, development and maturation patterns among species. (PMID:27282544)
• Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to X-Linked Acrogigantism. GPR101 encodes a class A G protein-coupled receptor that activates the 3’,5’-cyclic adenosine monophosphate signaling pathway. (PMID:29678281)
• Duplications of GPR101 gene are associated with X-linked acrogigantism and acromegaly; 924 G>C mutation is associated with sporadic acromegaly (PMID:30711029)
• findings demonstrate a fundamental role for GPR101 in mediating the leukocyte-directed actions of RvD5n-3 DPA. (PMID:31793912)
• GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11. (PMID:32958754)
• GPR101: Modeling a constitutively active receptor linked to X-linked acrogigantism. (PMID:38006624)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpr101	ENSDARG00000039218
mus_musculus	Gpr101	ENSMUSG00000036357
rattus_norvegicus	Gpr101	ENSRNOG00000027658
caenorhabditis_elegans	ser-5	WBGENE00008890

Paralogs (18): ADRB1 (ENSG00000043591), ADRA1A (ENSG00000120907), DRD2 (ENSG00000149295), ADRA2A (ENSG00000150594), ADRB2 (ENSG00000169252), ADRA1B (ENSG00000170214), ADRA1D (ENSG00000171873), OR5T3 (ENSG00000172489), OR56A1 (ENSG00000180934), OR5T1 (ENSG00000181698), OR5T2 (ENSG00000181718), OR56A4 (ENSG00000183389), ADRA2C (ENSG00000184160), OR56A3 (ENSG00000184478), OR13F1 (ENSG00000186881), OR56A5 (ENSG00000188691), ADRB3 (ENSG00000188778), ADRA2B (ENSG00000274286)

Protein

Protein identifiers

Probable G-protein coupled receptor 101 — Q96P66 (reviewed: Q96P66)

All UniProt accessions (1): Q96P66

UniProt curated annotations — full annotation on UniProt →

Function. Orphan receptor.

Subcellular location. Cell membrane.

Disease relevance. Pituitary adenoma 2, growth hormone-secreting (PITA2) [MIM:300943] A form of pituitary adenoma, a neoplasm of the pituitary gland and one of the most common neuroendocrine tumors. Pituitary adenomas are clinically classified as functional and non-functional tumors, and manifest with a variety of features, including local invasion of surrounding structures and excessive hormone secretion. Functional pituitary adenomas are further classified by the type of hormone they secrete. PITA2 is a growth hormone-secreting benign neoplasm, also known as somatotropinoma. It clinically results in acromegaly, a condition characterized by coarse facial features, protruding jaw, and enlarged extremities. Excessive production of growth hormone in children or adolescents before the closure of epiphyses causes gigantism, a condition characterized by abnormally tall stature. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_473362* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain

Pfam: PF00001

UniProt features (48 total): helix 12, topological domain 8, transmembrane region 7, strand 5, turn 4, compositionally biased region 3, sequence variant 3, region of interest 2, glycosylation site 2, chain 1, disulfide bond 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
8W8Q	ELECTRON MICROSCOPY	2.89
8W8R	ELECTRON MICROSCOPY	3.3
8W8S	ELECTRON MICROSCOPY	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96P66-F1	69.45	0.27

Antibody-complex structures (SAbDab): 2 — 8W8Q, 8W8R

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 104–182

Glycosylation sites (2): 7, 13

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 277 (showing top): BENPORATH_ES_WITH_H3K27ME3, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_ADENYLATE_CYCLASE_MODULATING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOBP_ADRENERGIC_RECEPTOR_SIGNALING_PATHWAY, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, TGGAAA_NFAT_Q4_01, LEIN_PONS_MARKERS, LEIN_MEDULLA_MARKERS, GOCC_RECEPTOR_COMPLEX, GOBP_ADENYLATE_CYCLASE_ACTIVATING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, GOMF_G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY, MEISSNER_NPC_HCP_WITH_H3K4ME2, MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED

GO Biological Process (4): positive regulation of MAPK cascade (GO:0043410), adenylate cyclase-activating adrenergic receptor signaling pathway (GO:0071880), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186)

GO Molecular Function (2): G protein-coupled receptor activity (GO:0004930), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), signaling receptor complex (GO:0043235), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
MAPK cascade	1
regulation of MAPK cascade	1
positive regulation of intracellular signal transduction	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
adrenergic receptor signaling pathway	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
binding	1
membrane	1
cell periphery	1
protein-containing complex	1
cellular anatomical structure	1

Protein interactions and networks

STRING

748 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPR101	AIP	O00170	684
GPR101	PRKAR1A	P10644	609
GPR101	MEN1	O00255	580
GPR101	GNRH1	P01148	523
GPR101	RBMX	P38159	522
GPR101	CDKN1B	P46527	521
GPR101	GHRH	P01286	519
GPR101	GNAS	Q5JWF2	511
GPR101	GPR26	Q8NDV2	506
GPR101	USP8	P40818	506
GPR101	GPR62	Q9BZJ7	487
GPR101	PDE11A	Q9HCR9	479
GPR101	GPR27	Q9NS67	474
GPR101	ARHGEF6	Q15052	447
GPR101	RBMX2	Q9Y388	447
GPR101	ASB12	Q8WXK4	447

IntAct

63 interactions, top by confidence:

A	B	Type	Score
AGPAT4	GPR101	psi-mi:“MI:0915”(physical association)	0.560
LAT	GPR101	psi-mi:“MI:0915”(physical association)	0.560
TM4SF4	GPR101	psi-mi:“MI:0915”(physical association)	0.560
CYB561A3	GPR101	psi-mi:“MI:0915”(physical association)	0.560
ORMDL3	GPR101	psi-mi:“MI:0915”(physical association)	0.560
GPR101	AGPAT4	psi-mi:“MI:0915”(physical association)	0.560
GPR101	TMEM147	psi-mi:“MI:0915”(physical association)	0.560
GPR101	NDUFB11	psi-mi:“MI:0915”(physical association)	0.560
GPR101	UNC93B1	psi-mi:“MI:0915”(physical association)	0.560
GPR101	DERL3	psi-mi:“MI:0915”(physical association)	0.560
SLC35E4	GPR101	psi-mi:“MI:0915”(physical association)	0.560
CDIPT	GPR101	psi-mi:“MI:0915”(physical association)	0.560
YIPF6	GPR101	psi-mi:“MI:0915”(physical association)	0.560
MFSD5	GPR101	psi-mi:“MI:0915”(physical association)	0.560
TMEM239	GPR101	psi-mi:“MI:0915”(physical association)	0.560
SLC41A1	GPR101	psi-mi:“MI:0915”(physical association)	0.560
GPR101	SLC39A9	psi-mi:“MI:0915”(physical association)	0.560
THSD7B	GPR101	psi-mi:“MI:0915”(physical association)	0.560
RTP2	GPR101	psi-mi:“MI:0915”(physical association)	0.560
	GPR101	psi-mi:“MI:0915”(physical association)	0.560
UNC93A	GPR101	psi-mi:“MI:0915”(physical association)	0.560
GPR101	GPX8	psi-mi:“MI:0915”(physical association)	0.400
GPR101	LMNB2	psi-mi:“MI:0915”(physical association)	0.400
ORMDL3	GPR101	psi-mi:“MI:0915”(physical association)	0.000
TMEM147	GPR101	psi-mi:“MI:0915”(physical association)	0.000
NDUFB11	GPR101	psi-mi:“MI:0915”(physical association)	0.000
UNC93B1	GPR101	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (26): GPR101 (Affinity Capture-MS), GPR101 (Affinity Capture-MS), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid), GPR101 (Two-hybrid)

ESM2 similar proteins: A1A5S3, F5HDK1, F5HF62, O00421, O12000, O18982, O35457, P09703, P16849, P32229, P49217, P49219, P49288, P51046, P52380, P52381, P56412, P69332, P69333, Q01035, Q03613, Q08520, Q0II78, Q0VDU3, Q14330, Q18LE5, Q3T0E9, Q4R613, Q61184, Q66673, Q6P7G9, Q6SW98, Q75ZH0, Q7TSN5, Q83207, Q86917, Q89609, Q8BZR0, Q8K1Z6, Q8TDV0

Diamond homologs: B2RPY5, B3DM66, O02664, O02836, O35210, O42384, O77408, O77590, O77621, P08908, P16395, P19327, P21917, P22270, P25095, P25104, P29754, P30555, P30556, P32250, P34969, P34976, P43240, P49019, P49146, P49220, P79113, P97295, Q0EAB6, Q0GBZ5, Q24563, Q25321, Q25322, Q25414, Q2YDN1, Q58CW4, Q5IS62, Q64264, Q6XXX9, Q6XXY0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

90 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	58
Likely benign	12
Benign	11

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
192259	NM_054021.2(GPR101):c.1098C>A (p.Asp366Glu)	Pathogenic

SpliceAI

163 predictions. Top by Δscore:

Variant	Effect	Δscore
X:137030482:G:C	donor_gain	0.9900
X:137030337:C:CC	acceptor_gain	0.9500
X:137030473:A:AC	donor_gain	0.9500
X:137030476:A:AC	donor_gain	0.9400
X:137030477:C:CC	donor_gain	0.9400
X:137030446:A:AC	donor_gain	0.9100
X:137030332:CAGCA:C	acceptor_gain	0.8700
X:137030534:G:GT	donor_gain	0.8700
X:137030335:CA:C	acceptor_gain	0.8600
X:137030481:AGCAG:A	donor_gain	0.8600
X:137030488:TTGC:T	donor_gain	0.8600
X:137030478:T:C	donor_gain	0.8400
X:137030454:G:C	donor_gain	0.8300
X:137030453:A:AC	donor_gain	0.8200
X:137030812:T:TA	donor_gain	0.8000
X:137030485:G:C	donor_gain	0.7900
X:137030586:A:AC	donor_gain	0.7900
X:137030587:C:CC	donor_gain	0.7900
X:137030896:CT:C	donor_gain	0.7900
X:137030895:A:AC	donor_gain	0.7600
X:137030896:C:CC	donor_gain	0.7600
X:137030334:GCA:G	acceptor_gain	0.7500
X:137030335:CAC:C	acceptor_gain	0.7500
X:137030336:ACTGC:A	acceptor_loss	0.7300
X:137030337:C:A	acceptor_loss	0.7300
X:137030338:T:C	acceptor_loss	0.7300
X:137030333:AGCA:A	acceptor_gain	0.7200
X:137030339:G:C	acceptor_loss	0.7100
X:137030808:T:TA	donor_gain	0.6900
X:137030492:A:AC	donor_gain	0.6600

AlphaMissense

3390 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:137030354:A:G	W441R	0.999
X:137030354:A:T	W441R	0.999
X:137031186:G:C	S163R	0.999
X:137031186:G:T	S163R	0.999
X:137031188:T:G	S163R	0.999
X:137031209:A:G	W156R	0.999
X:137031209:A:T	W156R	0.999
X:137031117:C:A	W186C	0.998
X:137031117:C:G	W186C	0.998
X:137031129:G:C	C182W	0.998
X:137031130:C:G	C182S	0.998
X:137031131:A:T	C182S	0.998
X:137031289:C:G	R129P	0.998
X:137031321:G:C	S118R	0.998
X:137031321:G:T	S118R	0.998
X:137031323:T:G	S118R	0.998
X:137031363:G:C	C104W	0.998
X:137031364:C:T	C104Y	0.998
X:137031457:A:G	L73P	0.998
X:137031459:G:C	N72K	0.998
X:137031459:G:T	N72K	0.998
X:137030438:C:G	G413R	0.997
X:137030438:C:T	G413R	0.997
X:137031064:G:C	P204R	0.997
X:137031130:C:T	C182Y	0.997
X:137031131:A:G	C182R	0.997
X:137031199:G:T	A159D	0.997
X:137031348:G:C	S109R	0.997
X:137031348:G:T	S109R	0.997
X:137031350:T:G	S109R	0.997

dbSNP variants (sampled 300 via entrez): RS1000455907 (X:137034933 G>A), RS1000716283 (X:137030074 G>A), RS1000826218 (X:137034324 A>G), RS1001543946 (X:137033286 C>T), RS1001971838 (X:137033668 C>T), RS1002662596 (X:137034129 G>C), RS1002786104 (X:137024120 A>C), RS1003573308 (X:137028599 CTG>C), RS1003626839 (X:137026805 A>C), RS1003645250 (X:137029212 G>C,T), RS1003835461 (X:137026148 T>C), RS1004477345 (X:137024855 G>C), RS1004578121 (X:137033310 G>A), RS1004613538 (X:137025211 A>C), RS1004712183 (X:137033640 G>T)

Disease associations

OMIM: gene MIM:300393 | disease phenotypes: MIM:300943, MIM:300942

GenCC curated gene-disease

Disease	Classification	Inheritance
pituitary adenoma, growth hormone-secreting, 2	Strong	X-linked
acromegaly	Supportive	Unknown

Mondo (3): pituitary adenoma, growth hormone-secreting, 2 (MONDO:0010492), X-linked acrogigantism due to Xq26 microduplication (MONDO:0010491), acromegaly (MONDO:0019933)

Orphanet (3): Acromegaly (Orphanet:963), X-linked acrogigantism (Orphanet:300373), OBSOLETE: X-linked acrogigantism due to Xq26 microduplication (Orphanet:448372)

HPO phenotypes

107 total (30 of 107 shown, HPO-id order):

HPO	Term
HP:0000044	Hypogonadotropic hypogonadism
HP:0000098	Tall stature
HP:0000158	Macroglossia
HP:0000164	Abnormality of the dentition
HP:0000238	Hydrocephalus
HP:0000276	Long face
HP:0000280	Coarse facial features
HP:0000293	Full cheeks
HP:0000303	Mandibular prognathia
HP:0000336	Prominent supraorbital ridges
HP:0000337	Broad forehead
HP:0000400	Macrotia
HP:0000445	Wide nose
HP:0000602	Ophthalmoplegia
HP:0000664	Synophrys
HP:0000687	Widely spaced teeth
HP:0000689	Dental malocclusion
HP:0000716	Depression
HP:0000739	Anxiety
HP:0000789	Infertility
HP:0000802	Impotence
HP:0000818	Abnormality of the endocrine system
HP:0000819	Diabetes mellitus
HP:0000822	Hypertension
HP:0000830	Anterior hypopituitarism
HP:0000845	Elevated circulating growth hormone concentration
HP:0000846	Adrenal insufficiency
HP:0000855	Insulin resistance
HP:0000869	Secondary amenorrhea
HP:0000870	Increased circulating prolactin concentration

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004904_214	Body mass index	1.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D000172	Acromegaly	C05.116.132.082; C10.228.140.617.738.250.100; C19.700.355.179

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523906 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class A Orphans with emerging pharmacology

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Catechin	affects cotreatment, increases expression	1
Aflatoxin B1	decreases methylation	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4883394	Binding	PRESTO-Tango GPCRome screening (GPR101)	Data for DCP probe UCSF924

Cellosaurus cell lines

1 cell lines: 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_KX19	PathHunter CHO-K1 GPR101 beta-arrestin	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

185 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00068029	PHASE4	COMPLETED	Pegvisomant And Sandostatin LAR Combination Study
NCT00068042	PHASE4	COMPLETED	A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
NCT00145405	PHASE4	COMPLETED	Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
NCT00149188	PHASE4	COMPLETED	Somatuline Autogel: Acromegaly Self/Partner Injection Study
NCT00151437	PHASE4	COMPLETED	Canadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00171886	PHASE4	COMPLETED	Octreotide Efficacy and Safety in First-line Acromegalic Patients
NCT00216398	PHASE4	COMPLETED	Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
NCT00242541	PHASE4	TERMINATED	Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
NCT00376064	PHASE4	COMPLETED	Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
NCT00461149	PHASE4	COMPLETED	Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
NCT00521300	PHASE4	COMPLETED	Preoperative Octreotide Treatment of Acromegaly
NCT00552071	PHASE4	COMPLETED	Ultrasound Guided Octreotide LAR Injection in Acromegaly
NCT00552851	PHASE4	UNKNOWN	Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
NCT00595140	PHASE4	COMPLETED	Acute Application of Pegvisomant and Octreotide in Acromegaly
NCT00627796	PHASE4	COMPLETED	Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
NCT00642720	PHASE4	COMPLETED	Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
NCT00701363	PHASE4	COMPLETED	Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
NCT01278342	PHASE4	COMPLETED	Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
NCT01424241	PHASE4	COMPLETED	Effects of Sandostatin LAR® in Acromegaly
NCT01618513	PHASE4	COMPLETED	Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
NCT01794793	PHASE4	COMPLETED	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
NCT01861717	PHASE4	TERMINATED	A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
NCT02060383	PHASE4	COMPLETED	Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing’s Disease or Acromegaly
NCT02427295	PHASE4	UNKNOWN	Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
NCT02668172	PHASE4	UNKNOWN	Pasireotide LAR and Pegvisomant Study in Acromegaly
NCT00128232	PHASE3	COMPLETED	Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
NCT00143416	PHASE3	COMPLETED	Long Term Study With B2036-PEG
NCT00210457	PHASE3	COMPLETED	Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00225979	PHASE3	COMPLETED	Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
NCT00372697	PHASE3	COMPLETED	Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
NCT00383708	PHASE3	COMPLETED	Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
NCT00444873	PHASE3	COMPLETED	Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
NCT00447499	PHASE3	COMPLETED	Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
NCT00499993	PHASE3	COMPLETED	Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
NCT00600886	PHASE3	COMPLETED	Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
NCT00616551	PHASE3	COMPLETED	Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
NCT00635765	PHASE3	COMPLETED	Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
NCT00642421	PHASE3	TERMINATED	Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
NCT00690898	PHASE3	COMPLETED	Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
NCT00765323	PHASE3	TERMINATED	Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly